Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
BMC Cancer. 2022 May 12;22(1):539. doi: 10.1186/s12885-022-09640-y.
Bronchoscopy can be a distress for the patient. There have been few studies on the combination of sedatives and opioids. The aim of this study was to demonstrate the usefulness and safety of administration of the combination of midazolam and pethidine during bronchoscopy.
In this prospective randomized single (patient)-blind study, we randomly assigned 100 patients who were scheduled to undergo bronchoscopy biopsy to receive treatment with either the midazolam/pethidine combination (combination group) or midazolam alone (midazolam group) during examinations. After the end of bronchoscopy, patients completed a questionnaire and the visual analogue scale was measured. The primary outcome was the patients' acceptance of re-examination assessed by visual analogue scale. We also assessed pain levels, vital signs, midazolam use, xylocaine use, and adverse events. Univariate analyses were performed using Fisher's exact test for categorical data, and the t-test or Mann-Whitney test was carried out for analysis of numeric data. All P-values were two-sided, and values < 0.05 were considered statistically significant.
We analyzed 47 patients in the combination group and 49 patients in the midazolam group. The primary outcome was a good trend in the combination group, but not significantly different (3.82 ± 2.3 in combination group versus 4.17 ± 2.75 in midazolam alone, P = 0.400). In the combination group, the visual analog scale score for pain during bronchoscopy was significantly lower (1.10 ± 1.88 versus 2.13 ± 2.42, P = 0.022), and the sedation level score per the modified observer's assessment of alertness/sedation scale was significantly deeper (3.49 ± 0.98 versus 3.94 ± 1.03, P = 0.031). Maximal systolic blood pressure during testing was significantly lower (162.39 ± 23.45 mmHg versus 178.24 ± 30.24 mmHg, P = 0.005), and the number of additional administrations of midazolam was significantly lower (2.06 ± 1.45 versus 2.63 ± 1.35, P = 0.049). There were also significantly fewer adverse events (30 versus 41, P = 0.036).
The combination uses of midazolam and pethidine for sedation resulted in significant improvements in the pain, blood pressure, additional use of midazolam, and safety during bronchoscopy among patients.
This study was registered in the University Medical Hospital Information Network in Japan (UMINCTR Registration number: UMIN000032230 , Registered: 13/April/2018).
支气管镜检查可能会给患者带来不适。目前关于镇静剂和阿片类药物联合应用的研究较少。本研究旨在证明咪达唑仑和哌替啶联合应用于支气管镜检查的有效性和安全性。
这是一项前瞻性、随机、单(患者)盲研究,我们将 100 名计划接受支气管镜活检的患者随机分为咪达唑仑/哌替啶联合治疗组(联合组)或咪达唑仑单药治疗组(咪达唑仑组)。支气管镜检查结束后,患者完成问卷调查并进行视觉模拟评分。主要结局是通过视觉模拟评分评估患者对再次检查的接受程度。我们还评估了疼痛程度、生命体征、咪达唑仑使用量、利多卡因使用量和不良反应。对于分类数据,使用 Fisher 确切检验进行单变量分析,对于数值数据,使用 t 检验或 Mann-Whitney 检验进行分析。所有 P 值均为双侧,P 值<0.05 认为具有统计学意义。
我们分析了联合组 47 例患者和咪达唑仑组 49 例患者。主要结局在联合组有良好的趋势,但无统计学差异(联合组 3.82±2.3,咪达唑仑组 4.17±2.75,P=0.400)。在联合组,支气管镜检查期间疼痛的视觉模拟评分明显较低(1.10±1.88 与 2.13±2.42,P=0.022),改良观察者警觉/镇静评分的镇静水平评分明显更深(3.49±0.98 与 3.94±1.03,P=0.031)。测试期间的最大收缩压明显较低(162.39±23.45mmHg 与 178.24±30.24mmHg,P=0.005),咪达唑仑的追加用量也明显较少(2.06±1.45 与 2.63±1.35,P=0.049)。不良反应的发生率也明显较低(30 例与 41 例,P=0.036)。
咪达唑仑和哌替啶联合镇静可显著改善支气管镜检查患者的疼痛、血压、咪达唑仑追加用量和安全性。
本研究在日本医科大学医院信息网络(UMINCTR 注册号:UMIN000032230 ,注册日期:2018 年 4 月 13 日)进行了注册。